Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1 CNS 1

Conditions

Pancreatic Neoplasms 1

Interventions

Oxaliplatin 297 Fluorouracil 272 Bevacizumab 235 Gemcitabine 234 Leucovorin 212 Capecitabine 204 pembrolizumab 200 Nivolumab 157 Irinotecan 156 Cisplatin 148 Specimen Handling 143 Magnetic Resonance Spectroscopy 130 130-nm albumin-bound paclitaxel 115 Paclitaxel 109 durvalumab 104 Cetuximab 102 Radiotherapy 96 atezolizumab 92 Biopsy 92 Drug Therapy 91 Albumin-Bound Paclitaxel 78 tislelizumab 77 Taxes 73 Folfox protocol 68 lenvatinib 67 Carboplatin 65 regorafenib 60 Blood Specimen Collection 60 trifluridine tipiracil drug combination 52 Ipilimumab 52

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Exenatide × Gastrointestinal × 1 year × Clear all

NCT05663515 2026-06-02

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡